… We included adult patients who required hospitalization for COVID-19 pneumonia. SARS-CoV-…
and symptoms that are associated with COVID-19 (cough, respiratory distress, dyspnea). …

… N-acetyl-cysteine (NAC) has been previously shown to exert beneficial effects in diverse …
potential impact in hospitalised patients with COVID-19 pneumonia, in terms of progression …

… blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe
acute respiratory syndrome caused by Coronavirus Disease 2019 (COVID-19). Clin. Infect. …

… Oral NAC administration (1200 mg/d) in patients with COVID-19 pneumonia reduces the
risk for mechanical ventilation and mortality [45]. NAC is inexpensive, has very low toxicity, has …

… of N acetyl cysteine (NAC), its use might be useful in COVID-19 patients by … We also reviewed
the use of NAC in COVID-19. … 53-year male, left lower lobe pneumonia, COVID 19 antibody …

… inflammatory activation during coronavirus disease (COVID-19) [3… During the COVID-19
pandemic research hypotheses on the … for SARS-CoV-2 pneumonia on short-term and long-term …

… of COVID-19 clinical manifestations might be associated with decreased GSH levels and the
consequent increased ROS production. Severe COVID-19 … with H1N1 influenza pneumonia; …

… coronavirus 2 (SARS… acetylcysteine (NAC) administration could restore this redox homeostasis
and suppress unfavorable evolution in patients with coronavirus disease 2019 (COVID-19…

… COVID-19, the findings suggest that NAC may be used to complement the management of
COVID-19 … ventilator-associated pneumonia and time to ventilator-associated pneumonia in 1 …

… A monocentric retrospective study on 1,083 patients hospitalized for COVID-19 pneumonia
found that patients receiving NAC on admission and administered at a dosage of 300 mg …